{"groups":[{"description":"CONDITIONING REGIMEN: Patients receive clofarabine IV over 2 hours on days -9 to -5 and melphalan IV over 30 minutes on day -4.\n\nTRANSPLANT: Patients undergo allogeneic hematopoietic stem cell transplant on day 0.\n\nGVHD PROPHYLAXIS: Beginning on day -3, patients receive tacrolimus IV or PO and sirolimus PO once daily with taper per City of Hope standard operating procedure.\n\nclofarabine: Given IV\n\nmelphalan: Given IV\n\nallogeneic hematopoietic stem cell transplantation: Undergo allogeneic hematopoietic stem cell transplant\n\ntacrolimus: Given IV or PO\n\nsirolimus: Given PO\n\nPharmacological Study: Correlative studies","id":"FG000","title":"Treatment (Clofarabine, Melphalan, Transplant)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"52"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"52"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"72 patients consented to the study. 52 of them became eligible and received the study treatment."}